tbuckley/cabot-search huggingface dataset:
List of Respiratory Protective Devices Approved by the Bureau of Mines
Authors: S.J. Pearce, L.B. Berger
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Subungual perineurioma: a peculiar location
Authors: R. Baran, C. Perrin
Journal: British Journal of Dermatology (2002)

We report the first case of subungual perineurioma presenting as clubbing of one finger, an unusual clinical feature. Histological study showed a myxoid tumour but with, unexpectedly, a diffuse expression of CD34. Differential diagnoses between perineurioma and myxoid soft tissue tumours expressing CD34 are discussed.
Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53
Authors: John Parant, Arturo Chavez-Reyes, Natalie A. Little, Wen Yan, Valerie Reinke, Aart G. Jochemsen, Guillermina Lozano
Journal: Nature Genetics (2001)
Abstract P384: The Impact of Optimal Therapy on Survival of Hospitalized Acute Decompensated Heart Failure: The ARIC Study
Authors: Patricia P Chang, Lisa M Wruck, Rachel A Kloss, Laura R Loehr, Stuart D Russell, Naresh M Punjabi, Alain G Bertoni, Edgar R Miller, Eyal Shahar, Wayne D Rosamond
Journal: Circulation (2015)

Background: Despite guidelines for the treatment of heart failure (HF), many patients remain undertreated. We hypothesized that patients hospitalized with acute decompensated HF (ADHF) who are prescribed “optimal” or “acceptable” HF therapy will have better overall survival compared to those on a “nonoptimal” medical regimen. Methods: The Atherosclerosis Risk in Communities (ARIC) Study conducted comprehensive surveillance of hospitalized HF events (age ≥55 years) in four US communities. “Optimal” pharmacotherapy was defined as ACE inhibitor or ARB, and beta-blocker, and/or aldosterone blocker; “acceptable” therapy was hydralazine and nitrate, and beta-blocker, and/or aldosterone blocker. Hospitalizations for HF from 2005-2011 were identified by ICD-9-CM codes, then validated by standardized physician review of hospital records, yielding 3575 hospitalizations validated as ADHF with left ventricular ejection fraction (EF) data, which corresponded to a weighted sample of 16,659 hospitalizations after accoun...
Assays for the detection of recent infections with human immunodeficiency virus type 1
Authors: G Murphy, J.  V. Parry
Journal: Eurosurveillance (2008)

The Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) is a generic term for several laboratory techniques that can be used to differentiate recent from long standing infections with human immunodeficiency virus-1 (HIV-1). There are several other approaches that identify acute seroconverters, but STARHS methods are distinguished by their ability to identify infections that occurred during an extended period of 4-6 months prior to sampling. While the STARHS techniques have been employed on an individual basis, their main usefulness lies in the potential of estimating the rate of acquisition of new HIV infection, or incidence, in a population by application to cross-sectional sero-surveys. This is substantially simpler and less expensive than cohort studies. As such, STARHS techniques facilitate the timely monitoring of the impact on HIV incidence of factors such as interventions, demographic factors and behavioural patterns. The major STARHS techniques currently available are described. Furthermore, the principles behind the methods used are discussed and the limitations of the current assays and the confounding factors that may affect assay specificity are described. A model algorithm for the application of a STARHS assay is shown. Finally, we outline recommendations for laboratory quality systems that will improve the efficiency of STARHS testing, reproducibility of results and reliability of incidence estimates.
276. Evaluation of an Oncolytic Adenovirus: Efficacy Studies on Primary Human Tumor Cell Cultures and Safety Studies in Non-Human Primates
Authors: Shawn E. Lupold, Ronald Rodriguez
Journal: Molecular Therapy (2004)

There is a great need for agents that target therapeutic agents, such as viral vectors, to prostate cancer cells. We have used phage display to identify short disulfide-constrained heptapeptides that bind specifically to the extracellular-portion of the Prostate Specific Membrane Antigen (PSMA), a type II integral membrane protein over-expressed on the surface of prostate cancer cells. Two separate phage display peptide strategies were applied, in parallel, to purified PSMA protein bound to two separate substrates. We reasoned that peptide sequences common to both substrate selections would be specific binders of PSMA. Additionally, the design allowed for stringent cross selections, where phage populations from one selection condition could be applied to the alternative substrate. These strategies resulted in a series of phage displayed peptides able to bind to PSMA by ELISA and direct binding assays, both with purified protein and in prostate cancer cells. PSMA specific cell binding is competitively inhibited by soluble, purified PSMA. The synthesized peptides are capable of binding PSMA protein and enhancing its carboxypeptidase enzymatic activity, suggesting protein folding stabilization. The discovery of these peptides provides the foundation for subsequent development of peptide targeted therapeutics against prostate cancer.
TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice
Authors: Dou Zhang, Vinciane Gaussin, George E. Taffet, Narasimhaswamy S. Belaguli, Miho Yamada, Robert J. Schwartz, Lloyd H. Michael, Paul A. Overbeek, Michael D. Schneider
Journal: Nature Medicine (2000)
Estimation of a disease progression model for COPD using data from the ECLIPSE study
Authors: Alex Exuzides, Chris Colby, Andrew Briggs, David Lomas, Maureen Rutten van-Molken, Maggie Tabberer, Mike Chambers, Hana Muellerova, Nick Locantore, Nancy Risebrough, Sebastian Gonzalez-McQuire
Journal: European Respiratory Journal (2013)

OBJECTIVES: Develop a statistical model to predict disease progression and outcomes in COPD patients using the ECLIPSE database.  METHODS: Based on a conceptual model of COPD disease progression and outcomes and data from 2,164 COPD patients we estimated associations between central attributes of disease progression (exacerbations, lung function, exercise capacity and symptoms) and outcomes (SGRQ and survival) while adjusting for baseline characteristics (co-morbidities, BMI, fibrinogen, history of exacerbations, smoking, age and gender). Random coefficient models were applied to estimate the longitudinal association between central attributes in order to describe disease progression. Non-linear functional forms were used characterize the nature of the data. Endogeneity among the central attributes of the CM was addressed by use of time-lagging in the regression models.  RESULTS: Moderate & severe exacerbations were associated with a decline in FEV1 of 8ml and 10 ml (P  CONCLUSIONS: We have developed a COPD disease progression model that represents associations between the central attributes of the disease and their impact on health status and mortality.  Sponsored by GlaxoSmithKline RD Study SCO104960).
Relation Between Mammary-Gland Responses to Lactogenic Hormone Combinations and Tumor Susceptibility in Various Strains of Mice&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Satyabrata Nandi, Howard A. Bern
Journal: JNCI Journal of the National Cancer Institute (1960)

The mammary glands of 12-week-old female mice of 10 strains and sublines of differing mammary-cancer susceptibility were studied in intact, hypophysectomized-ovariectomized and hypophysectomized-ovariectomized animals given lactogenic hormonal combinations that included somatotropin or mammotropin. Variations occurred in normal mammary-gland morphology among the different strains, but these could not be correlated with the mammary-cancer susceptibility of the strain. Regression of the mammary parenchyma occurred after hypophysectomy-ovariectomy in all strains examined. In all mice treated with estrogen plus progesterone plus mammotropin followed by mammotropin plus cortisol, lobuloalveolar development and lactogenesis occurred. The degree of response varied in different strains, but the variations could not be correlated with mammary-cancer susceptibility. In mice treated with estrogen plus progesterone plus somatotropin followed by somatotropin plus cortisol, lobuloalveolar development and lactogenesis occurred in genetically susceptible strains that show a high mammary-tumor incidence in both virgin and parous females. No such response was obtained in genetically susceptible strains with a high incidence only in parous females. The lobuloalveolar and lactational responses to somatotropin appear to be modified quantitatively by the presence or absence of the mammary-tumor agent.
Abstract 3055: Potential role of cyclin D1 in regulation of liver cancer stem cells
Authors: Wei Xia, Xiao Qi Wang
Journal: Cancer Research (2014)

Abstract Cancer stem cells (CSCs) are capable of self-renewal, multipotency, in vivo tumorigenicity, and driving metastasis. CSCs are more resistant to conventional therapy, allowing recurrence of tumor. Thus, novel therapies capable of eliminating CSCs are needed. Cyclin D1 is deregulated in many types of cancers. Beyond being a cell cycle regulator and oncogene, cyclin D1 also enhances stem cell (SC) self-renewal and promotes induced pluripotent stem cells (iPSCs) reprogramming efficiency. Yet, the role of cyclin D1 in regulation of CSC is not well defined. Here we investigated whether and how cyclin D1 could regulate liver cancer CSC properties. We overexpressed cyclin D1 in two lines of HCC cells, Huh7 and 97H and found that the sphere formation capacity was enriched in Huh7 cyclin D1-expressing cells than Huh7 cells. From dissected single spherical cells, the secondary sphere formation capacity was significantly higher in cyclin D1-expressing cells than both parental Huh7 (p=0.00) and 97H (p=0.02) cells. Anchorage-independent spherical colonies (spheres) are composed of a small number of cancer cells with stem-like properties. Thus, the results suggest that overexpression of cyclin D1 enhanced self-renewal capacity of liver CSCs. The cyclin D1-expressing spheres displayed an increased expression of stem cell-associated genes Nanog, Oct4, and Nordal/Activin. Smad2/3, a TGF-β signaling effector, was highly phosphorylated in cyclin D1-expressing spheres compared to monolayer or spheres without cyclin D1 expression. More importantly, TGF-β/Smad inhibitor (SB431542) inhibited cyclin D1-expressing CSC self-renewal shown by significantly reduction of sphere formation in two lines of cyclin D1-expressing HCC lines, whereas it had no effects on sphere formation in parental cells without cyclin D1 overexpression. In addition, Erk inhibitor (UO126) showed no inhibiting effects, a further proof of the role of cyclin D1 mediated activation of Smad2/3. These results indicate that TGF-β/Smad inhibitor might have therapeutic potential for targeting liver CSCs. HCC cells are highly resistance chemotherapy resulting in enriched CSC population. We further investigated the sphere formation capacity of D1-expressing cells under the treatment of chemotherapeutic agents in combination with Smad inhibitor. We found that SB431542 could inhibit cyclin-D1 expressing spherical cancer cell proliferation therefore sensitized the cells to chemo drug cisplatin. In summary, our results suggest that cyclin D1 might promote liver CSC proliferation and self-renewal via activation of TGF-β/Smad signaling, with underlining mechanism is under investigation. Citation Format: Wei Xia, Xiao Qi Wang. Potential role of cyclin D1 in regulation of liver cancer stem cells. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3055. doi:10.1158/1538-7445.AM2014-3055
CD44 expression is regulated by translocation and promoter hypermethylation in gastric lymphoma
Authors: Xiaotong Hu, Ac T. Liang, Y. W. Chen, Q. Tao, W. Y. Au, Ml Y. Wong, L. Shen, K. Y. Wong, Ts K. Wan, W. L. Cheung, K. M. Chu, L. C. Chan, Y. L. Kwong, Rh S. Liang, G. Srivastava
Journal: Cancer Research (2006)

Proc Amer Assoc Cancer Res, Volume 47, 2006

4197 

One of the major genetic features of non-Hodgkin’s lymphomas (NHL) is the chromosomal translocation, most frequently involving the immunoglobulin heavy chain ( IGH ) gene at band 14q32. By employing the IgH dual color, break apart rearrangement probe (Vysis Inc.) for interphase FISH; followed by the long-distance inverse polymerase chain (LDI-PCR) strategy, we identified CD44 at chromosome 11p13 as a novel translocation partner gene of IGH in primary GL. The IGH/CD44 t (11;14)(p13;q32) was detected in 40% (4/10) mucosa-associated lymphoid tissue (MALT) lymphoma (3 positive cases are transformed MALT lymphoma cases) and 10% (4/40) diffuse large B-cell lymphoma (DLBCL) cases. This finding makes CD44 as the first cell adhesion molecule involving the IGH translocation and the third gene identified that involves the IGH translocation in MALT lymphoma. Immunohistochemistry showed that CD44 was expressed strongly in the membrane and cytoplasm of the tumor cells in 40% (4/10) MALT cases and 67.5% (27/40) DLBCL cases, including 8 IGH/CD44 translocation positive cases, while the remaining cases showed very weak or no CD44 expression. We next determined whether the hypermethylation of the promoter region of CD44 gene was responsible for the downregulation of CD44 in GL cases lacking CD44 expression. We first analyzed 10 mature B-cell lymphoma cell lines for the CD44 methylation status by methylation-specific PCR (MSP) and bisulfite genomic sequencing (BGS). Methylated alleles were detected in all the cell lines lacking CD44 expression but not in cell lines with CD44 expression. The treatment of the cell lines lacking CD44 with the demethylation agent 5-Aza-dC restored the CD44 expression. In the GL cases, methylated alleles were detected in 42% (21/50) cases and they significantly correlated with weak or no CD44 protein expression in the tumor cells. The most interesting observation was that the 3 CpG sites contained by E2F, Sp1 and EGR1 were nearly always methylated in cell lines lacking CD44 expression but not in the cell lines with CD44 expression. Similar results were also found in the GL cases. The correlation of CD44 expression and clincopathological parameters showed that strong CD44 expression was associated with poor prognosis in GL, and the cases with unmethylated CD44 were positively correlated with high stage (p=0.023). Overall, our results show that CD44 expression is regulated by different mechanisms operating simultaneously in GL, chromosomal translocation in cases with strong CD44 expression and gene silencing by promoter hypermethylation in cases lacking CD44 .
Abstract 18124: The Role of SCN5A Mutations in J Wave Syndromes
Authors: Dan Hu, Hector Barajas-Martinez, Ryan Pfeiffer, Elena Burashnikov, Gabriel Caceres, Charles Antzelevitch
Journal: Circulation (2010)

Introduction: Brugada syndrome (BrS), Early repolarization syndrome (ERS), and some forms of ventricular fibrillation represent a continuous spectrum of phenotypic expression that we recently propo...
Abstract 4679: Impact of a Chronic Total Occlusion in a Non-Infarct Related Artery on Long-Term Mortality in Patients With Diabetes Mellitus After ST Elevation Myocardial Infarction
Authors: Bimmer E Claessen, Rene J van der Schaaf, Karel T Koch, Marije M Vis, Jan Baan, Martijn M Meuwissen, Jan G Tijssen, Robbert J de Winter, Jan J Piek, Jose P Henriques
Journal: Circulation (2009)

Background: Recently, the presence of a chronic total occlusion (CTO) in a noninfarct-related artery (IRA), and not mere multivessel disease (MVD) was reported to be an independent predictor of mor...
Abstract 12908: Alpha-1 Anti-trypsin Inhibits the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction
Authors: Antonio Abbate, Benjamin W Van Tassell, Sanah Christopher, Nayef Abouzaki, Chiara Sonnino, Claudia Oddi, Salvatore Carbone, Ryan Melchior, Charlotte Roberts, Michael C Kontos, Mary Ann Peberdy, Stefano Toldo, Charles Dinarello
Journal: Circulation (2014)

Introduction: Alpha-1 anti-trypsin (AAT) is an anti-inflammatory protein abundant in the plasma. Studies in mice have shown anti-inflammatory and cardioprotective properties of plasma derived AAT in experimental myocardial infarction (MI). Hypothesis: Plasma derived AAT (Prolastin C) inhibits the acute inflammatory response in patients with ST-segment elevation myocardial infarction (STEMI). Methods: Ten patients with acute STEMI were enrolled in an open-label single-arm treatment study of Prolastin C at 60 mg/kg intravenously within 12 hours of admission. High-sensitivity C reactive protein (CRP) and plasma AAT levels were determined at admission, 72 hours and 14 days, and followed clinically for up to 12 weeks for the occurrence of new onset heart failure (HF), recurrent MI or death. Twenty patients with STEMI enrolled in 2 prior clinical trials with identical inclusion criteria, and were randomly assigned to placebo served as historical controls. Data is presented as median and interquartile range, and...
“Kits” for male contraceptive pill
Authors: Abi Berger
Journal: BMJ (2000)

The male contraceptive pill could become a reality after some surprising findings from California. Molecular biologists at the Salk Institute in La Jolla have been studying cellular communication systems.

Dr Tony Hunter and his team have been investigating the ways cells respond when stem cell factor binds to kit/SCF-R, a tyrosine kinase receptor that sits across cell membranes.

“We already know that when stem cell factor binds to this particular receptor, signalling processes are triggered that result in the production of healthy red blood cells, melanocytes, and gametes,” said Dr Hunter.

Dr Hunter's team set out to investigate exactly what role one of the many receptor activated signalling pathways has …
Liability for Adverse Events in Direct-to-Consumer Advertising
Authors: David Shein
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Queensland Lung Cancer Screening Study: Interium Results
Authors: H. Marshall, Rv. Bowman, J. Crossin, M. Fuentes, R. Slaughter, L. Passmore, L. McCaul, D. Courtenay, M. Webb, M. Windsor, Ia. Yang, P. V. Zimmerman, T. Hayes, S. Redmond, K. M. Fong
Journal: Journal of Thoracic Oncology (2011)
Sialic Acid Content of the Erythrocyte and of an Ascites Tumor Cell of the Mouse
Authors: Aaron Miller, John F. Sullivan, Jay H. Katz
Journal: Cancer Research (1963)

The sialic acid content of the mouse erythrocyte was compared with that of the Ehrlich ascites carcinoma cell. Neuraminidase treatment of intact tumor cells yielded 36 times more sialic acid than was released from the erythrocyte on a per cell basis. If this were all located on the surface, it may be calculated that the density of sialic acid on the Ehrlich ascites carcinoma cell is about 4 times greater than that on the erythrocyte. Trypsin released a sialic acid-containing fragment from both types of cells, the sialic acid being in the “bound” form. The sialic acid released by trypsin treatment of Ehrlich ascites tumor cells was only about one-sixth of that released by neuraminidase. By contrast, approximately equal amounts were liberated from the erythrocytes by these two enzymes. The erythrocyte sialic acid-containing substance was nondialyzable and was not precipitated by trichloroacetic acid. N -acetylneuraminic acid constituted approximately 70 per cent and N -glycolyneuraminic acid the remaining 30 per cent of the sialic acid of the tumor cell as determined by paper chromatography. In the erythrocyte N -acetylneuraminic acid constituted almost all the sialic acid, N -glycolylneuraminic acid being undetectable in this cell.